Fabrikstrasse 2, 4056 Basel
Novartis   link
Location: Basel
Discipline: Pharmacology

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.


Pharmacology - Health - Nov 17
Patients & Caregivers Healthcare Professionals Society & ESG - Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF, compared to valsartan 1 -   Entresto, compared to valsartan, demonstrated reduced risk in total heart failure hospitalizations and cardiovascular death in
Pharmacology - Health - Nov 15

Patients & Caregivers Healthcare Professionals Society & ESG Sickle cell pain crises are unpredictable, severe events associated with life-threatening complications 1 -   Adakveo reduced the annual rate of sickle cell pain crises by 45% compared to placebo (1.63 vs 2.98) and

Pharmacology - Health - Nov 13

Patients & Caregivers Healthcare Professionals Society & ESG - The strategy is aligned with the Novartis Access Principles, which aim to systematically integrate access strategies in how the company researches, develops and delivers medicines globally -   A newly formed sub-Saharan Africa u

Health - Pharmacology - Nov 12

Patients & Caregivers Healthcare Professionals Society & ESG Interim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/ARP Annual Meeting US analysis of long-term financial impact when switching to biosimilar etanercept

Pharmacology - Health - Nov 5

Ziextenzo(TM) is indicated to decrease the incidence of febrile neutropenia, one of the most serious side effects of chemotherapy - With approval of Ziextenzo(TM) , Sandoz is first and only company to offer US physicians longand short-acting filgrastim biosimilar treatment options -   With four U

Pharmacology - Health - Nov 15

Patients & Caregivers Healthcare Professionals Society & ESG - If approved, Mayzent (siponimod) will be the first and only oral treatment specifically indicated for patients with active secondary progressive multiple sclerosis (SPMS) in Europe ) -   CHMP opinion is based on the Phase III EX

Pharmacology - Health - Nov 12

Patients & Caregivers Healthcare Professionals Society & ESG - 42.2% of patients with non-radiographic axial spondyloarthritis (nr-axSpA) treated with Cosentyx had improved ASAS40 scores through Week 16; improvements continued through Week 52 -   PREVENT is the largest ever study of

Pharmacology - Health - Nov 11

Patients & Caregivers Healthcare Professionals Society & ESG - The FLIGHT- FXR phase IIb study showed tropifexor, a highly potent non-bile acid FXR agonist, produces robust and dose-dependent reductions in hepatic fat and alanine aminotransferase compared to placebo at 12 weeks -   These da

Pharmacology - Health - Nov 1

Cosentyx narrowly missed statistical significance for superiority in ACR 20, the primary endpoint of the EXCEED trial, while showing numerically higher results versus Humira * -   Statistically significant advantages of Cosentyx versus Humira * in psoriatic arthritis (PsA)-specific endpoints were

Job Offers

» Job Offer: Novartis

Last job offers

website preview


Medicine and Life Sciences